QUOTE AND NEWS
Benzinga  May 8  Comment 
Aeterna Zentaris (NASDAQ: AEZS) announces the results of the vote on directors held earlier today at its annual meeting of shareholders. Issuers listed on the Toronto Stock Exchange are required to issue a news release providing this information....
FierceBiotech  Apr 19  Comment 
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each...
Benzinga  Apr 17  Comment 
Aeterna Zentaris Inc. (NASDAQ: AEZS) (the "Company") today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its...
StreetInsider.com  Apr 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Aeterna+Zentaris+%28AEZS%29+Names+David+Dodd+as+CEO/8251862.html for the full story.
Benzinga  Apr 10  Comment 
Aeterna Zentaris Inc. (NASDAQ: AEZS) (the "Company") today presented encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models....
StreetInsider.com  Apr 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Aeterna+Zentaris+%28AEZS%29%2C+Ergomed+Enter+Co-Development+Agreement+for+AEZS-108/8243875.html for the full story.
StreetInsider.com  Mar 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Aeterna+Zentaris%2C+Inc.+%28AEZS%29+Tops+Q4+EPS+by+2c/8204880.html for the full story.
StreetInsider.com  Mar 11  Comment 
China Auto Logistic Inc. (Nasdaq: CALI) 82.3% HIGHER; moving higher, potentially due in part to a bullish blog post issued Monday morning. Elecsys Corporation (Nasdaq: ESYS) 29.7% HIGHER; reported Q3 EPS of $0.18, versus $0.07 reported last year....
FierceBiotech  Mar 11  Comment 
Canada's Aeterna Zentaris ($AEZS) took another bad hit today after it announced that it is scuttling a Phase III study of perifosine for relapsed/refractory multiple myeloma. The move came after the drug safety monitoring board decided that there...
Benzinga  Mar 11  Comment 
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki